May 24
Transcatheter Aortic Valve Implantation Update
Objectives: To discuss the technique of TAVR; to critically analyze the data resulting from TAVR trials.

Speaker: Paul Teirstein, MD
Chief of Cardiology
Director, Interventional Cardiology
Scripps Clinic
La Jolla, CA

June 28
Advancements in Treating Hypertension
Objectives: To delineate magnitude clinical relevance of hypertension; To outline three major pathophysiology and application to hypertensive theory; to discuss recent treatment guidelines (ISHIB, AHA) and trials (ACCORD, ACCOMPLISH, onTARGET); and to Review aspects of refractory hypertension and treatment.

Speaker: Christian W. Mende, MD, FACP, FACN, FASN, FASH
Clinical Professor of Medicine
University of California, San Diego
Specialist in Clinical Hypertension
Diplomate American Board of Internal Medicine and Nephrology
San Diego, California

July 26
Performance Improvement Lecture (1 of 3)
Objectives: To code patients correctly to ensure accurate registry data; To contact all patients tasked to them through the AEHR and schedule appropriate labs and follow up; To develop and implement evidenced based guidelines regarding cholesterol management for patients with known CAD; and to measure physician performance against agreed upon guidelines.

Speaker: Douglas Triffon, MD
Medical Director, Lipid Clinic
Scripps Clinic, Scripps Green Hospital
La Jolla, California

August 23
Management of patients with HCM: The 2011 ACC/AHA Guidelines
Objectives: To describe the current diagnosis of HCM; To discuss the current medical treatment and goals of therapy; To review the appropriate timing of invasive therapies; To describe indications, contraindications and outcomes of alcohol septal ablation.

Speaker: Srihari S. Naidu, MD
Director, Cardiac Catheterization Laboratory
Director, Interventional Cardiology Fellowship Program
Winthrop University Hospital

September 27
Controversies in the treatment of aortic valve disease
Objectives: To discuss the management of asymptomatic patients with severe disease; To describe the role of TAVI; and To review the management of patients with far-advanced VHD.

Speaker: Blasé Carabello, MD
Vice Chair
Chief of Medicine, Michael E. DeBakey VA Medical Center
Bellaire, Texas

October 25
Peptide therapy for Heart Failure
Objectives: TBA

Speaker: John Burnett, MD
Mayo Clinic
Rochester, MN

Calendar continued on next page
November 22  
Performance Improvement Lecture (2 of 3)  
Objectives: To code patients correctly to ensure accurate registry data; To contact all patients tasked to them through the AEHR and schedule appropriate labs and follow up; To develop and implement evidenced based guidelines regarding cholesterol management for patients with known CAD; and to measure physician performance against agreed upon guidelines.

Speaker: Christopher Suhar, MD  
Scripps Clinic  
La Jolla, California

December 27 – Cancelled

Accreditation Statements (also displayed on-site)

Accreditation Statement
Scripps Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Scripps Health designates this live activity for a maximum number of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Overall Grand Rounds in Cardiovascular Diseases Course Learning Objectives:
- Summarize current guidelines for the treatment of cardiovascular diseases.
- Update physicians with respect to newer approaches to the treatment of cardiovascular diseases, specifically in the sub-specialties of congestive heart failure, electrophysiology, non-invasive imaging, interventional cardiology, congenital heart disease, and peripheral vascular disease.
- Review skills to appropriately diagnose and treat cardiovascular disease using evidence-based data.

Faculty Disclosure
Scripps Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME). In accordance with the ACCME Standards for Commercial Support, Scripps Health has implemented a process where everyone in control of the educational content of the activity must disclose all relevant financial relationships with any commercial interest that they or their spouse/partner may have had within the last 12 months. For this purpose we consider the relevant financial relationships of the spouse or partner to be that of the speakers as well. If a speaker refuses to disclose relevant financial relationships, they will be disqualified from being a part of the planning and implementation of this CME activity.

<table>
<thead>
<tr>
<th>Course Director/Speaker(s)/Planning Committee/CME Planning</th>
<th>Company Name/Commercial Interest</th>
<th>Nature of Relevant Financial Relationship (i.e. employee, consultant, stock holder, board member, speakers bureau, consultant, etc.)</th>
<th>What Was Received (i.e. honorarium, research support, intellectual property rights, stock options, travel expenses, etc.–amounts NOT required)</th>
<th>Investigational/Unlabeled Product/Usage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Price (Course Director)</td>
<td>Boston Scientific, Sanofi Aventis, Accumetrics, AstraZeneca Daiichi Sanyko/Eli Lilly</td>
<td>Speaker bureau Research support Consultant, speaker</td>
<td>Honorarium Grant Honorarium Honorarium</td>
<td>None</td>
</tr>
<tr>
<td>J. Thomas Heywood (Planning Committee)</td>
<td>GlaxoSmithKline, Medtronic AstraZeneca, Novartis St. Jude Synvista</td>
<td>Speaker, consultant Speaker, consultant Speaker</td>
<td>Honorarium Honorarium and research grant Honorarium Fellowship support, research grant Research grant</td>
<td>None</td>
</tr>
<tr>
<td>CME Staff</td>
<td>None</td>
<td>N/A</td>
<td>N/A</td>
<td>None</td>
</tr>
</tbody>
</table>

Educational Grants
This course is supported, in part, by educational grants from industry, in accordance with ACCME Standards. Appropriate acknowledgement will be given to all supporters at the time of the educational activity.

Cultural and Linguistic Competency
This activity is in compliance with California Assembly Bill 1195 which requires that all CME activities comprising a patient care element include curriculum addressing the topic of cultural and linguistic competency. The intent of this bill is to ensure that health care professionals are able to meet the cultural and linguistic concerns of a diverse patient population through effective and appropriate professional development. Cultural and linguistic competency was incorporated into the planning of this activity. For additional information regarding California Assembly Bill 1195 please visit www.scripps.org/clinicalcss to access the Cultural and Linguistic Competency Guide.
For additional information and to view available course brochures, please visit Scripps Conference Services & CME at:
Phone: 858-652-5400   Fax: 858-652-5565 Med.edu@scrippshealth.org  http://www.scripps.org/conferenceservices